Ge Zijun, Lal Sean, Le Thi Y L, Dos Remedios Cris, Chong James J H
Bosch Institute, The University of Sydney, Sydney, Australia.
Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Biophys Rev. 2015 Mar;7(1):127-139. doi: 10.1007/s12551-014-0148-0. Epub 2014 Dec 3.
The discovery of multiple classes of cardiac progenitor cells in the adult mammalian heart has generated hope for their use as a therapeutic in heart failure. However, successful results from animal models have not always yielded similar findings in human studies. Recent Phase I/II trials of c-Kit (SCIPIO) and cardiosphere-based (CADUCEUS) cardiac progenitor cells have demonstrated safety and some therapeutic efficacy. Gaps remain in our understanding of the origins, function and relationships between the different progenitor cell families, many of which are heterogeneous populations with overlapping definitions. Another challenge lies in the limitations of small animal models in replicating the human heart. Cryopreserved human cardiac tissue provides a readily available source of cardiac progenitor cells and may help address these questions. We review important findings and relative unknowns of the main classes of cardiac progenitor cells, highlighting differences between animal and human studies.
在成年哺乳动物心脏中发现多种类型的心脏祖细胞，为将其用于治疗心力衰竭带来了希望。然而，动物模型的成功结果在人体研究中并非总能得到类似的发现。最近关于c-Kit（SCIPIO）和基于心球（CADUCEUS）的心脏祖细胞的I/II期试验已证明其安全性和一定的治疗效果。我们对不同祖细胞家族的起源、功能及相互关系的理解仍存在差距，其中许多是定义重叠的异质群体。另一个挑战在于小型动物模型在复制人类心脏方面存在局限性。冷冻保存的人类心脏组织提供了易于获取的心脏祖细胞来源，可能有助于解决这些问题。我们回顾了心脏祖细胞主要类别的重要发现和相关未知之处，强调了动物研究和人体研究之间的差异。
